Literature DB >> 15465986

Relationship of variability in residual symptoms with recurrence of major depressive disorder during maintenance treatment.

Jordan F Karp1, Daniel J Buysse, Patricia R Houck, Christine Cherry, David J Kupfer, Ellen Frank.   

Abstract

OBJECTIVE: To investigate how residual symptoms from an index episode of major depressive disorder may be associated with recurrence, the authors conducted a trial involving four maintenance treatment approaches and examined 1) whether the level and variability of residual symptoms differed among the maintenance treatment conditions and 2) whether greater symptom variability is associated with a higher likelihood of recurrence and more rapid recurrence.
METHOD: Patients enrolled in a maintenance treatment study (N=114) were randomly assigned to one of four maintenance treatment conditions: imipramine plus interpersonal psychotherapy, imipramine alone, interpersonal psychotherapy alone, or no active treatment. Residual symptoms were characterized both as continuous variables (mean values and coefficients of variation for Hamilton Depression Rating Scale and Global Assessment Scale [GAS] scores) and as a categorical variable, the percentage of maintenance evaluations with a Hamilton depression scale score > or =8 (e.g., with a symptom peak).
RESULTS: Analysis of variance revealed no differences among the four treatment conditions in patients' levels of residual symptoms or symptom variability assessed as a continuous variable, but patients in the combined treatment group had fewer symptom peaks, compared to those in the placebo and interpersonal psychotherapy groups. Cox proportional hazards modeling showed that higher coefficients of variation for both the Hamilton depression scale and the GAS scores and a greater percentage of evaluations with symptom peaks were associated with shorter survival times.
CONCLUSIONS: A higher level of symptom variability during maintenance treatment is associated with higher risk for recurrence of depression and may provide a specific target for maintenance treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465986     DOI: 10.1176/ajp.161.10.1877

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  21 in total

1.  The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Authors:  D N Kiosses; G S Alexopoulos
Journal:  Psychol Med       Date:  2012-05-21       Impact factor: 7.723

2.  Heritability of insomnia symptoms in youth and their relationship to depression and anxiety.

Authors:  Philip R Gehrman; Lisa J Meltzer; Melisa Moore; Allan I Pack; Michael L Perlis; Lindon J Eaves; Judy L Silberg
Journal:  Sleep       Date:  2011-12-01       Impact factor: 5.849

Review 3.  Partial remission, residual symptoms, and relapse in depression.

Authors:  E S Paykel
Journal:  Dialogues Clin Neurosci       Date:  2008       Impact factor: 5.986

4.  Relationship between sleep disturbance and recovery in patients with borderline personality disorder.

Authors:  David T Plante; Frances R Frankenburg; Garrett M Fitzmaurice; Mary C Zanarini
Journal:  J Psychosom Res       Date:  2013-02-11       Impact factor: 3.006

5.  Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort?

Authors:  Wilfred R Pigeon; Mark Hegel; Jürgen Unützer; Ming-Yu Fan; Michael J Sateia; Jeffrey M Lyness; Cindy Phillips; Michael L Perlis
Journal:  Sleep       Date:  2008-04       Impact factor: 5.849

6.  The significance of treating somatic symptoms on functional outcome improvement in patients with major depressive disorder: a post hoc analysis of 2 trials.

Authors:  Thomas N Wise; Adam L Meyers; Durisala Desaiah; Craig H Mallinckrodt; Michael J Robinson; Daniel K Kajdasz
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

7.  Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

Authors:  Alexandre Y Dombrovski; Jill M Cyranowski; Benoit H Mulsant; Patricia R Houck; Daniel J Buysse; Carmen Andreescu; Michael E Thase; Alan G Mallinger; Ellen Frank
Journal:  Depress Anxiety       Date:  2008       Impact factor: 6.505

8.  Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.

Authors:  Ramin Saghafi; Charlotte Brown; Meryl A Butters; Jill Cyranowski; Mary Amanda Dew; Ellen Frank; Ariel Gildengers; Jordan F Karp; Eric J Lenze; Francis Lotrich; Lynn Martire; Sati Mazumdar; Mark D Miller; Benoit H Mulsant; Elizabeth Weber; Ellen Whyte; Jennifer Morse; Jacqueline Stack; Patricia R Houck; Salem Bensasi; Charles F Reynolds
Journal:  Int J Geriatr Psychiatry       Date:  2007-11       Impact factor: 3.485

Review 9.  Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age.

Authors:  Henry C Driscoll; Jordan F Karp; Mary Amanda Dew; Charles F Reynolds
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

10.  [Neurobiological subtypes of geriatric depression. Their importance for diagnosis and treatment].

Authors:  M A Rapp
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.